Alphamab Oncology (9966) Financial Statements

2 Followers

Alphamab Oncology Financial Overview

Alphamab Oncology's market cap is currently HK$8.33B. The company's EPS TTM is HK$-0.11; its P/E ratio is -15.87; Alphamab Oncology is scheduled to report earnings on March 25, 2026, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	¥ 551.58M	¥ 640.08M	¥ 218.77M	¥ 166.84M	¥ 146.02M
Gross Profit	¥ 426.67M	¥ 579.77M	¥ 163.54M	¥ 122.64M	¥ 142.99M
Operating Income	¥ -149.32M	¥ 101.01M	¥ -305.55M	¥ -432.37M	¥ -415.62M
EBITDA	¥ -86.31M	¥ 156.79M	¥ -129.30M	¥ -391.83M	¥ -358.13M
Net Income	¥ -110.99M	¥ 166.34M	¥ -210.59M	¥ -325.72M	¥ -412.42M
Balance Sheet
Cash & Short-Term Investments	¥ 1.35B	¥ 1.57B	¥ 1.41B	¥ 1.35B	¥ 1.99B
Total Assets	¥ 2.10B	¥ 2.24B	¥ 2.14B	¥ 2.12B	¥ 2.71B
Total Debt	¥ 123.03M	¥ 185.96M	¥ 257.08M	¥ 345.39M	¥ 637.27M
Net Debt	¥ -135.90M	¥ -926.16M	¥ -828.91M	¥ -723.80M	¥ -166.04M
Total Liabilities	¥ 386.33M	¥ 409.87M	¥ 465.00M	¥ 559.86M	¥ 834.80M
Stockholders' Equity	¥ 1.71B	¥ 1.83B	¥ 1.67B	¥ 1.56B	¥ 1.87B
Cash Flow
Free Cash Flow	¥ -153.48M	¥ 190.56M	¥ -239.02M	¥ -429.96M	¥ -478.72M
Operating Cash Flow	¥ -121.89M	¥ 212.34M	¥ -202.84M	¥ -300.31M	¥ -320.60M
Investing Cash Flow	¥ -628.85M	¥ -92.93M	¥ -18.11M	¥ 850.76M	¥ 574.26M
Financing Cash Flow	¥ -98.31M	¥ -98.96M	¥ 218.07M	¥ -310.90M	¥ 363.90M

Currency in CNY

Alphamab Oncology Earnings and Revenue History

Income Statement >

Alphamab Oncology Debt to Assets

Balance Sheet >

Alphamab Oncology Cash Flow

Cash Flow >

Alphamab Oncology Forecast EPS vs Actual EPS

Earnings >